Lirum Therapeutics, Inc.
Novel drug candidates for debilitating diseases with proprietary mechanisms of action
- Sector
- Biotech
- Headquarters
- NEW YORK, NY
- Founded
- 2021
- Latest Form D
- $6.3M, Feb 2023
- Total capital
- $6.3M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $6.3M
- 1 Form D · last Feb 2023
- 44 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 12 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$6.3M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Daniel HumeDirectorNamed in SEC Form D filings
- Ivan BergsteinDirectorNamed in SEC Form D filings
- Kenneth HobermanExecutive Officer, DirectorNamed in SEC Form D filings
- Mark SardDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 12- PendingTreating Autoimmune Diseases With Insulin-like Growth Factor 1 Receptor Ligand Conjugated To An AgentUSPTOApplication 18876854
- PendingMethods For Treating Inflammatory Conditions Of The Eye With An IGF-1R Ligand Conjugated To A Disease-modifying AgentUSPTOApplication 18876858
- PendingMethods For Treating IGF-1R-RELATED Cancers With An Insulin-like Growth Factor 1 Receptor Ligand Conjugated To A Cytotoxic AgentUSPTOApplication PCTUS2024031615
Show all 12 patent records
- Treating Autoimmune Diseases With Insulin-like Growth Factor 1 Receptor Ligand Conjugated To An AgentDec 4, 2025 · Application 18876854Pending
- Methods For Treating Inflammatory Conditions Of The Eye With An IGF-1R Ligand Conjugated To A Disease-modifying AgentJun 26, 2025 · Application 18876858Pending
- Methods For Treating IGF-1R-RELATED Cancers With An Insulin-like Growth Factor 1 Receptor Ligand Conjugated To A Cytotoxic AgentApplication PCTUS2024031615Pending
- Methods For Treating IGF-1R-RELATED Pediatric Cancers With An Insulin-like Growth Factor 1 Receptor Ligand Conjugated To A Cytotoxic AgentApplication PCTUS2024031601Pending
- Methods For Treating IGF-1R-RELATED Pediatric Cancers With An Insulin-like Growth Factor 1 Receptor Ligand Conjugated To A Cytotoxic AgentApplication 63550463Pending
- Methods For Treating IGF-1R-RELATED Cancers With An Insulin-like Growth Factor 1 Receptor Ligand Conjugated To A Cytotoxic AgentApplication 63550459Pending
- Methods For Treating Inflammatory Conditions Of The Eye With An Insulin-like Growth Factor 1 Receptor Ligand Conjugated To A Disease-modifying AgentApplication PCTUS2023069428Pending
- Methods For Treating Autoimmune Diseases With An Insulin-like Growth Factor 1 Receptor Ligand Conjugated To A Disease-modifying AgentApplication PCTUS2023069425Pending
- Methods For Treating IGF-1R-RELATED Pediatric Cancers With An Insulin-like Growth Factor 1 Receptor Ligand Conjugated To A Cytotoxic AgentApplication 63505263Pending
- Methods For Treating IGF-1R-RELATED Cancers With An Insulin-like Growth Factor 1 Receptor Ligand Conjugated To A Cytotoxic AgentApplication 63505345Pending
- Methods For Treating IGF-1R-RELATED Pediatric Cancers With An Insulin-like Growth Factor 1 Receptor Ligand Conjugated To A Cytotoxic AgentApplication 19488387Pending
- Methods For Treating IGF-1R-RELATED Cancers With An Insulin-like Growth Factor 1 Receptor Ligand Conjugated To A Cytotoxic AgentApplication 19488347Pending
Related companies, and why
- Valted Seq, Inc.Similar federal contract value in Biotech · null in contracts
- INSAMO INC.Similar federal contract value in Biotech · null in contracts
- Ancilia Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- Persist AI Formulations CorpSimilar federal contract value in Biotech · null in contracts
- Hapten Sciences Development, LLCSimilar federal contract value in Biotech · null in contracts
- Digit Technologies Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .